


| | OD | os |
|--------------------|--------------------------------|---|
| Lids/Lashes | normal | Mild swelling and redness |
| Conjunctiva/Sclera | White and quiet | 1+ injection |
| Cornea | Normal, contact lens in place | 2mm x 3.5mm area of opacity with surrounding infiltrate just outside of visual axis inferiorly, underlying stromal edema, overlying 2mm area of epi defec |
| Anterior Chamber | Deep and quiet | 1+ cell |
| Iris | Normal shape, size, morphology | Normal shape, size, morphology |
| Lens | clear | clear |
| Vitreous | clear | clear |



FLAUM







Epidemiology


US based studies in 1950s-1980s: 11.0 per 100,000 people
Recent studies: 20.9 to 27.6 per 100,000 person-years
Contact lens wearers: 130.4 per 100,000 person-years
38.5 million contact lens wearers in the US

Contact lens wear is the single greatest risk factor for developing keratitis in the United States


Eins, J. C., Nevit, M. P., Hodge, D. O. & Ballard, D. J. Incidence of uiceralive keratitis in a defined population from 1950 through 1988. Arch. Ophthalmod. 111, 1055-71 (1980)
Gentleman State of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 121, 1023-21 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Indicaca Contact Users. Porthamod. 1951. M. J. Colic Eng. Ophthalmod. 213, 1022-8 (2010).
Bratini, Base of Ches. Incidence of Ches. 1951. M. J. D. Contact Incidence of Ches. 1951. M. J. D. Contact Incidence Ches. 1951. M. J. D. Contact Incidence of Ches. 1951. M. J. D. Contact Incidence Ches. 1951. M. J













































Healthy eyes do not develop spontaneous keratitis!


Need to have a compromised ocular surface:

-Direct injury (trauma, surgery)


-Any eye disease that leads to breakdown of the surface
Dry eye
Recurrent erosions
Corneal dystrophies
Corneal dedema
Herpetic infections


-Patients who don't heal well
Diabetics
Immunocompromised
Elderly












































































Original Investigation

Early Addition of Topical Corticosteroids in the Treatment of Bacterial Keratitis

Kathryn J. Ray, MA; Muthiah Srinivasan, MD, Jeena Mascarenhas, MD; Revathi Rajaraman, MD; Meenakkin Ravindram, MD; David V. Gidddon, PhD; Catherine E. Oldenburg, MPH; Catherine Q, Sun, BS; Mkhade E. Zegars, MD, Stephen D. McLeod, MD; Nohan R. Achraya, MD; Thomas M, Leitman, MD

Sub-analysis of SCUT trial data:

3 month best spectacle-corrected acuity

Steroids: 3 days within diagnosis vs 4 or more days

FLAUM

Severe ulcers:

- 3 line improvement if administered within 2-3 days (p=.02)
- 2 line improvement if administered after 4 days (p=.17)

Moderate ulcers:

1 line improvement if administered with 2-3 days (p=.09) 2 lines worse if administered after 4 days (p=.01)

Mild ulcers

No significant improvement compare to placebo 2 lines worse if administered after 4 days (p=.01)

Severe: CF vision Moderate: 20/40-20/800 Mild: <20/40

FLAUM

FLAUM

Conclusions

- Corneal ulcers require prompt evaluation and treatment
- Obtain thorough history remember healthy eyes do not develop keratitis.
- Cultures and smears should be obtained, even if treatment has started
- Antibiotic resistance is prevalent fortified antibiotics give the broadest coverage, particularly for gram positive organisms
- Steroids may provide some benefit with respect to scarring if initiated early



